| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 5.626 | 39.986 | 46.008 | 32.374 | 40.746 | 2.694 | 91.239 | 109.215 |
| Total Income - EUR | - | - | 5.626 | 39.986 | 46.008 | 32.379 | 40.746 | 2.694 | 91.881 | 110.143 |
| Total Expenses - EUR | - | - | 584 | 3.337 | 5.747 | 15.166 | 10.573 | 6.418 | 20.433 | 26.837 |
| Gross Profit/Loss - EUR | - | - | 5.042 | 36.649 | 40.261 | 17.213 | 30.173 | -3.724 | 71.447 | 83.306 |
| Net Profit/Loss - EUR | - | - | 4.873 | 35.450 | 39.344 | 16.912 | 29.538 | -3.821 | 59.736 | 80.013 |
| Employees | - | - | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 |
Check the financial reports for the company - Oncoplus S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 57 | 806 | 316 | 2.200 | 1.344 | 539 | 28.440 | 20.201 |
| Current Assets | - | - | 5.252 | 35.087 | 39.981 | 15.464 | 28.891 | 2.798 | 39.417 | 63.847 |
| Inventories | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 278 |
| Receivables | - | - | 0 | 26.588 | 20.584 | 405 | 23.200 | 1.023 | 361 | 52.845 |
| Cash | - | - | 5.252 | 8.499 | 8.860 | 15.059 | 5.691 | 1.776 | 39.055 | 1.677 |
| Shareholders Funds | - | - | 4.917 | 35.493 | 39.395 | 16.962 | 29.587 | 2.948 | 62.675 | 80.062 |
| Social Capital | - | - | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | 392 | 400 | 902 | 702 | 649 | 390 | 5.181 | 3.987 |
| Income in Advance | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Oncoplus S.r.l.